Renaissance Capital logo

ENTX News

Oral drug developer Entera Bio prices $11 million IPO at $8, the low end of the range

Entera Bio logo

Entera Bio, which is developing oral formulations of treatments for a thyroid condition and osteoporosis, raised $11.2 million by offering 1.4 million units at $8, the low end of the range of $8 to $10. Existing shareholders bought $3.4 million of the IPO (30%)....read more

Entera Bio revives estimated $55 million IPO with updated financials

Entera Bio logo

Entera Bio, which is developing oral formulations of treatments for a thyroid condition and osteoporosis, reported financial results for the twelve months ended December 31, 2017, in an amendment filed with the SEC on Thursday. It originally set terms for a...read more

Oral drug developer Entera Bio postpones $55 million IPO

Entera Bio logo

Entera Bio, which is developing oral formulations of treatments for a thyroid condition and osteoporosis, postponed its IPO on Monday. It had filed to raise $55 million by offering 5.0 million shares at a price range of $10 to $12, for a proposed post-IPO...read more

US IPO Week Ahead: 10 IPOs expected to price, led by PagSeguro's $1.8 billion deal

ENTX

Ten deals are expected to price next week, raising a combined $3.1 billion in proceeds, as this month gears up to be the busiest January in over eight years in terms of proceeds raised ($3.1 billion raised to date). The week will be headlined by the "Paypal...read more